A recent study reveals that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise regimens.
Published data in a leading health publication demonstrates that while overweight individuals can lose about a fifth of their total mass while on the medication, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Users using these treatments must be aware of the risk of fast weight regain when the treatment is stopped," warns researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to original mass in about 18 months.
Analyzing Therapies
The research, which examined dozens of studies involving thousands of participants, contrasted the results of GLP-1 agonists with other pills.
Researchers note that people who lose weight through dieting generally see a more gradual creep back—perhaps 100 grams monthly—once they finish.
Explaining the Fast Regain
Experts suggest the mechanism of the jabs is key to understanding the amplified weight return.
These medications imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication leads to appetite is no longer kept in check, making binge eating a significant risk."
A Chronic Condition?
Health authorities recommend the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, given the high risk of relapse, the treatment should be considered ongoing.
This perspective is supported by pharmaceutical companies, who state that the results "emphasize the persistent character of excess weight," comparing it to managing conditions like diabetes.
User Experiences
People who have discontinued the jabs explain a intense resurgence of appetite.
"It was like a trigger flipping and I was suddenly ravenous," recalled an individual.
This challenge is worsened if patients have not developed sustainable dietary or behavioural modifications during therapy.
Growing Adoption
Survey data indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Use is higher among women than males.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, clinicians caution that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and maintained weight loss likely depends on integrated lifestyle support.
